Celecoxib, a Cyclooxygenase-2 (COX-2) inhibitor, has been shown to suppress tumor cell viability through disruption of PDK-1/Akt signaling and induction of apoptosis (Kucab et al., 2005; Zhou et al., 2018). The gene discussed is PTGS2; the disease is neoplasm.